scispace - formally typeset
Search or ask a question
Author

Michal Bromberg

Bio: Michal Bromberg is an academic researcher. The author has contributed to research in topics: Medicine & Cross-sectional study. The author has an hindex of 1, co-authored 1 publications receiving 1079 citations.

Papers
More filters
Journal ArticleDOI
A. Danielle Iuliano1, Katherine Roguski1, Howard H. Chang2, David Muscatello3, Rakhee Palekar4, Stefano Tempia1, Cheryl Cohen5, Jon Michael Gran6, Jon Michael Gran7, Dena L. Schanzer, Benjamin J. Cowling8, Peng Wu8, Jan Kynčl, Li Wei Ang9, Minah Park8, Monika Redlberger-Fritz10, Hongjie Yu11, Laura Espenhain12, Anand Krishnan13, Gideon O. Emukule1, Liselotte van Asten, Susana Silva, Suchunya Aungkulanon14, Udo Buchholz15, Marc-Alain Widdowson1, Joseph S. Bresee1, Eduardo Azziz-Baumgartner, Po-Yung Cheng, Fatimah S. Dawood, Ivo M. Foppa, Sonja J. Olsen, Michael Haber, Caprichia Jeffers, C. Raina MacIntyre, Anthony T. Newall, James G. Wood, Michael Kundi, Therese Popow-Kraupp, Makhdum Ahmed, Mahmudur Rahman, Fatima Marinho, C Viviana Sotomayor Proschle, Natalia Vergara Mallegas, Feng Luzhao, Li Sa, Juliana Barbosa-Ramírez, Diana Malo Sanchez, Leandra Abarca Gomez, Xiomara Badilla Vargas, aBetsy Acosta Herrera, María Josefa Llanés, Thea Kølsen Fischer, Tyra Grove Krause, Kåre Mølbak, Jens Nielsen, Ramona Trebbien, Alfredo Bruno, Jenny Ojeda, Hector Ramos, Matthias an der Heiden, Leticia del Carmen Castillo Signor, Carlos Enrique Serrano, Rohit Bhardwaj, Mandeep S. Chadha, Venkatesh Vinayak Narayan, Soewarta Kosen, Michal Bromberg, Aharona Glatman-Freedman, Zalman Kaufman, Yuzo Arima, Kazunori Oishi, Sandra S. Chaves, Bryan O. Nyawanda, Reem Abdullah Al-Jarallah, Pablo A Kuri-Morales, Cuitláhuac Ruiz Matus, Maria Eugenia Jimenez Corona, Alexander Burmaa, Oyungerel Darmaa, Majdouline Obtel, Imad Cherkaoui, Cees C van den Wijngaard, Wim van der Hoek, Michael G Baker, Don Bandaranayake, Ange Bissielo, Sue Huang, Liza Lopez, Claire Newbern, Elmira Flem, Gry M Grøneng, Siri Hauge, Federico G de Cosío, Yadira De Molto, Lourdes Moreno Castillo, María Agueda Cabello, Marta Von Horoch, José L. Medina Osis, Ausenda Machado, Baltazar Nunes, Ana Paula Rodrigues, Emanuel Rodrigues, Cristian Calomfirescu, Emilia Lupulescu, Rodica Popescu, Odette Popovici, Dragan Bogdanovic, Marina Kostic, Konstansa Lazarevic, Zoran Milosevic, Branislav Tiodorovic, Mark I-Cheng Chen, Jeffery Cutter, Vernon J. Lee, Raymond T. P. Lin, Stefan Ma, Adam L. Cohen, Florette K. Treurnicht, Woo Joo Kim, Concha Delgado-Sanz, Salvador de mateo Ontañón, Amparo Larrauri, Inmaculada León, Fernando Vallejo, Rita Born, Christoph Junker, Daniel Koch, Jen-Hsiang Chuang, Wan-Ting Huang, Hung-Wei Kuo, Yi-Chen Tsai, Kanitta Bundhamcharoen, Malinee Chittaganpitch, Helen K. Green, Richard Pebody, Natalia Goñi, Hector Chiparelli, Lynnette Brammer, Desiree Mustaquim 
TL;DR: These global influenza-associated respiratory mortality estimates are higher than previously reported, suggesting that previous estimates might have underestimated disease burden.

1,658 citations

Journal ArticleDOI
TL;DR: The more pronounced VE decline coincided with rapid increase in Omicron variant activity, and rate reduction of breakthrough complications remained moderate to high throughout the evaluation.
Abstract: We estimated vaccine effectiveness (VE) of the BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com) booster dose against SARS-CoV-2 infection and reduction of complications (hospitalization, severe disease, and death) among breakthrough cases in persons in Israel >16 years of age for <20 weeks. VE estimates reached 96.8% (95% CI 96.0%–97.5%) for persons 16–59 years of age and 93.1% (95% CI 91.8%–94.2%) for persons >60 years of age on week 3. VE estimates remained at these levels for 8 weeks in the 16–59 age group and 11 weeks in those >60. A slow decline followed, becoming more pronounced in the last 2–3 weeks of evaluation. Estimates in the last week of evaluation were 77.6% (95% CI 68.4%–84.2%) and 61.3% (52.5%–68.4%) for persons 16–59 years and >60 years, respectively. The more pronounced VE decline coincided with rapid increase in Omicron variant activity. Rate reduction of breakthrough complications remained moderate to high throughout the evaluation.

15 citations

Journal Article
01 Apr 2022
TL;DR: The virological component of the surveillance system showed the SARS-CoV-2 community spread, but had low sensitivity when virus activity was low, and Sentinel surveillance can assist in monitoring future novel pandemics and should be augmented in revised preparedness plans.
Abstract: BACKGROUND Guidelines for pandemic preparedness emphasize the role of sentinel and syndromic surveillance in monitoring pandemic spread. OBJECTIVES To examine advantages and obstacles of utilizing a sentinel influenza surveillance system to monitor community severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity based on Israel's experience from mid-March to mid-May 2020. METHODS Several modifications were applied to the influenza surveillance system. The clinical component relied mainly on pneumonia and upper respiratory infection (URI) consultations with primary care physicians as well as visits to emergency departments (ED) due to pneumonia. The virological data were based on nasopharyngeal swabs obtained from symptomatic patients who visited outpatient clinics. RESULTS By week 12 of the pandemic, the crude and age-specific primary physician consultation rates due to URI and pneumonia declined below the expected level, reaching nadir that lasted from week 15 until week 20. Similarly, ED visits due to pneumonia were significantly lower than expected from weeks 14 and 15 to week 20. The virological surveillance started on week 13 with 6/253 of the swabs (2.3%) positive for SARS-CoV-2. There was a peak of 13/225 positive swabs on week 145.8%. During weeks 17-20, none of the swabs (47-97 per week) were positive for SARS-CoV-2. This trend was similar to national data. CONCLUSIONS The virological component of the surveillance system showed the SARS-CoV-2 community spread, but had low sensitivity when virus activity was low. The clinical component, however, had no yield. Sentinel surveillance can assist in monitoring future novel pandemics and should be augmented in revised preparedness plans.

2 citations


Cited by
More filters
Journal ArticleDOI
Gregory A. Roth1, Gregory A. Roth2, Degu Abate3, Kalkidan Hassen Abate4  +1025 moreInstitutions (333)
TL;DR: Non-communicable diseases comprised the greatest fraction of deaths, contributing to 73·4% (95% uncertainty interval [UI] 72·5–74·1) of total deaths in 2017, while communicable, maternal, neonatal, and nutritional causes accounted for 18·6% (17·9–19·6), and injuries 8·0% (7·7–8·2).

5,211 citations

Journal ArticleDOI
TL;DR: The findings show substantial progress in the reduction of lower respiratory infection burden, but this progress has not been equal across locations, has been driven by decreases in several primary risk factors, and might require more effort among elderly adults.
Abstract: Summary Background Lower respiratory infections are a leading cause of morbidity and mortality around the world The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study 2016, provides an up-to-date analysis of the burden of lower respiratory infections in 195 countries This study assesses cases, deaths, and aetiologies spanning the past 26 years and shows how the burden of lower respiratory infection has changed in people of all ages Methods We used three separate modelling strategies for lower respiratory infections in GBD 2016: a Bayesian hierarchical ensemble modelling platform (Cause of Death Ensemble model), which uses vital registration, verbal autopsy data, and surveillance system data to predict mortality due to lower respiratory infections; a compartmental meta-regression tool (DisMod-MR), which uses scientific literature, population representative surveys, and health-care data to predict incidence, prevalence, and mortality; and modelling of counterfactual estimates of the population attributable fraction of lower respiratory infection episodes due to Streptococcus pneumoniae, Haemophilus influenzae type b, influenza, and respiratory syncytial virus We calculated each modelled estimate for each age, sex, year, and location We modelled the exposure level in a population for a given risk factor using DisMod-MR and a spatio-temporal Gaussian process regression, and assessed the effectiveness of targeted interventions for each risk factor in children younger than 5 years We also did a decomposition analysis of the change in LRI deaths from 2000–16 using the risk factors associated with LRI in GBD 2016 Findings In 2016, lower respiratory infections caused 652 572 deaths (95% uncertainty interval [UI] 586 475–720 612) in children younger than 5 years (under-5s), 1 080 958 deaths (943 749–1 170 638) in adults older than 70 years, and 2 377 697 deaths (2 145 584–2 512 809) in people of all ages, worldwide Streptococcus pneumoniae was the leading cause of lower respiratory infection morbidity and mortality globally, contributing to more deaths than all other aetiologies combined in 2016 (1 189 937 deaths, 95% UI 690 445–1 770 660) Childhood wasting remains the leading risk factor for lower respiratory infection mortality among children younger than 5 years, responsible for 61·4% of lower respiratory infection deaths in 2016 (95% UI 45·7–69·6) Interventions to improve wasting, household air pollution, ambient particulate matter pollution, and expanded antibiotic use could avert one under-5 death due to lower respiratory infection for every 4000 children treated in the countries with the highest lower respiratory infection burden Interpretation Our findings show substantial progress in the reduction of lower respiratory infection burden, but this progress has not been equal across locations, has been driven by decreases in several primary risk factors, and might require more effort among elderly adults By highlighting regions and populations with the highest burden, and the risk factors that could have the greatest effect, funders, policy makers, and programme implementers can more effectively reduce lower respiratory infections among the world's most susceptible populations Funding Bill & Melinda Gates Foundation

1,147 citations

Journal ArticleDOI
TL;DR: In this article, a comprehensive overview of pandemics and their effects is provided to help contextualise the COVID-19 pandemic, its impact on tourism and government, industry and consumer response.
Abstract: Disease outbreaks and pandemics have long played a role in societal and economic change. However, the nature of such change is selective, meaning that it is sometimes minimal and, at other times, and change or transformation may be unexpected, potentially even reinforcing contemporary paradigms. A comprehensive overview of pandemics and their effects is provided. This is used to help contextualise the COVID-19 pandemic, its impact on tourism and government, industry and consumer response. Drawing on the available literature, factors that will affect tourism and destination recovery are then identified. Some measures will continue or even expand present growth orientations in tourism while others may contribute to sustainability. It is concluded that that the selective nature of the effects of COVID-19 and the measures to contain it may lead to reorientation of tourism in some cases, but in others will contribute to policies reflecting the selfish nationalism of some countries. However, the response to planetary limits and sustainable tourism requires a global approach. Despite clear evidence of this necessity, the possibility for a comprehensive transformation of the tourism system remains extremely limited without a fundamental transformation of the entire planet.

661 citations

Journal ArticleDOI
TL;DR: These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America in 2009 and address new information regarding diagnostic testing, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal influenza.
Abstract: These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America (IDSA) in 2009, prior to the 2009 H1N1 influenza pandemic. This document addresses new information regarding diagnostic testing, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal influenza. It is intended for use by primary care clinicians, obstetricians, emergency medicine providers, hospitalists, laboratorians, and infectious disease specialists, as well as other clinicians managing patients with suspected or laboratory-confirmed influenza. The guidelines consider the care of children and adults, including special populations such as pregnant and postpartum women and immunocompromised patients.

496 citations